Nalpropion Pharmaceuticals LLC
Reporting payments is a legal requirement; large totals often reflect large product portfolios.
$54Kgeneral payments (2019-2025)
$0.00research payments (2019-2025)
2,298clinicians paid
General and research payments are shown separately, never blended. Research payments are often institution-directed and tied to clinical trials.
General payments by year
General payments only, as reported to CMS. Research payments are totaled above and not included in these bars.
Specialties it works with most
Clinicians with the largest reported totals
Often long-running consulting, speaking, or advisory relationships, which companies must report by law. A large total is not evidence of anything improper.
| Clinician | Location | Specialty | General payments (2019-2025) |
|---|---|---|---|
| Ken Fujioka | San Diego, CA | Endocrinology, Diabetes & Metabolism | $157.36 |
| Raymond Plodkowski | San Diego, CA | Endocrinology, Diabetes & Metabolism | $156.70 |
| Michelle Welch | Shavano Park, TX | Endocrinology, Diabetes & Metabolism | $125.71 |
| Delliah Stampp | Las Cruces, NM | Family Medicine | $120.37 |
| Conchita Paz | Las Cruces, NM | Family Medicine | $120.37 |
| Sergio Huerta | Las Cruces, NM | Family Medicine | $120.37 |
| Aurthur Guerrero | Schertz, TX | Endocrinology, Diabetes & Metabolism | $114.45 |
| Daniel Katselnik | Shavano Park, TX | Endocrinology, Diabetes & Metabolism | $112.18 |
| Dorota Malinowski | Shavano Park, TX | Endocrinology, Diabetes & Metabolism | $111.10 |
| Karen Frankwich | Mission Viejo, CA | Endocrinology, Diabetes & Metabolism | $108.47 |
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.